Juliette L.
- Country
- France
- Department
- Hématologie
Research Overview
- An ALFA 2101 multicenter randomized phase II study: CPX-351 versus intensive chemotherapy in patients with de novo intermediate or adverse risk AML stratified by genomics
- Phase I/II Evaluation of Sulfasalazine, Idarubicin, and Cytarabine in Newly Diagnosed Non-Favorable Acute Myeloid Leukemia Patients Aged 60 and Above
- Comparison of Apixaban, Rivaroxaban, and Acetylsalicylic Acid for Thromboembolic Prevention in JAK2V617F-Positive Myeloproliferative Neoplasms
Data & Insights
Has run more than one trial at 29 of 148 partner sites.
Specializations
Acute Myeloid Leukemia Research
This investigator specializes in developing innovative therapeutic approaches for acute myeloid leukemia (AML), with particular emphasis on treating both newly diagnosed and relapsed/refractory cases.
- Novel Combination Therapies
- FLT3-Mutated AML Treatment
- Elderly Patient Care
Their research encompasses targeted therapies including gilteritinib and Gemtuzumab Ozogamicin combinations.
Advanced Treatment Strategies
The investigator focuses on developing sophisticated treatment protocols incorporating chemotherapy optimization and molecular targeting approaches.
- Remission Assessment Protocols
- Genomic Stratification
- Minimal Residual Disease Monitoring
Their work includes evaluation of deep remission achievements and standardized response assessment methods.
Hematologic Malignancies
The investigator's expertise extends to myeloproliferative neoplasms and their complications, with focus on preventive strategies.
- Thromboembolic Prevention
- JAK2V617F-Positive Disorders
- Chronic Myeloid Conditions
Their research includes investigation of anticoagulation strategies in Philadelphia-negative myeloproliferative disorders.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.